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ABSTRACT
Autopsy is the gold standard for establishing the cause of death. We present results of the largest retrospective
review of complete autopsies of subjects after hematopoietic stem cell transplantation to better define the role
of the autopsy in discovering a missed diagnosis. We reviewed the medical chart and autopsy records of 111
patients who had undergone hematopoietic stem cell transplantation from July 1986 to June 2003 from a single
center. We compared the cause of death as charted by the clinical team with data obtained from postmortem
chart review and autopsy reports. Of 29 (26%) cases when the premortem and postmortemmajor diagnoses did
not agree, only 4 (4%) autopsy records provided data that might have led to the initiation of new treatments,
and none of these diagnoses would be missed today with more sensitive and specific diagnostics and improved
supportive care. Although autopsies after transplantation can be important educational, research, and epide-
miologic tools and provide an emotional benefit to patient’s families, in our series they rarely provided missed
diagnoses that would alter the management of subsequent patients. Improvements in noninvasive tests for
relapse or occult infections may further erode the role of autopsies in discovering missed diagnoses.
© 2007 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Autopsy remains the gold standard for establishing
ause of death. However, rates of performing autop-
ies have decreased in general medical and surgical
ards [1,2]. Different reasons have been postulated for
his decline including lower rates of consent from
elatives, legal issues concerning exposing physicians’
rrors and lack of reimbursement [3]. However, as
utopsy rates decrease, the ability to conﬁrm a clinical
iagnosis or document a missed diagnosis may be lost.
It has been reported that the possibility that a
iven autopsy will reveal important unsuspected diag-
oses has decreased over time. Based on their review
rom 1966 to 2002 in general medical and surgical
atients, Shojania et al [1] estimated that a contempo-
ary United States institution could expect missed
iagnoses involving a principal cause of death at a rate
f 4.1% to 6.7%. Al Saidi et al [4] examined the utility
f autopsy in preventing death in 28 patients who o
6nderwent hematopoietic stem cell transplantation
HSCT) from 1994 to 1999. They found 10 (35%)
iscrepancies between pre- and postmortem diagnoses
ut only 2 discrepancies that would have inﬂuenced
atient management and none that would have altered
atient outcome.
We present the largest review of complete autop-
ies of subjects after HSCT with a focus on the clinical
tility of the autopsy as a method of improving sub-
equent patient care. We hypothesized that results
rom autopsies performed speciﬁcally on cases after
SCT rarely lead to additional information that
ould have changed management.
ETHODS
We performed an institutional review board ap-
roved retrospective electronic and paper chart review
n 111 subjects after HSCT who underwent autopsy
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Utility of Autopsy after Hematopoietic Stem Cell Transplantation 27t Loyola University Medical Center from July 1986
o June 2003. Progress notes and death certiﬁcates
ere reviewed to determine the treating team’s pro-
osed cause of death. The autopsy report, electronic
nd paper medical records, and microbiologic results
ere reviewed to determine the actual cause of death.
2-person independent chart review was performed
o compare the cause of death as charted in the med-
cal record by the attending or fellow on service with
ata obtained from chart review and autopsy reports.
Goldman et al [5] published criteria to review
utopsy reports for missed diagnoses. Major diagnoses
ncluded the principal underlying disease(s) and pri-
ary cause(s) of death; minor diagnoses were all other
mportant conditions. A missed major diagnosis was
eﬁned as a difference between the clinical team’s
ain cause of death, documented by the fellow or
ttending, and the cause of death as determined by
eview of the electronic and paper charts and the
utopsy results. A class I missed major diagnosis was
hat for which detection before death would in all
robability have led to a change in management and
his might have resulted in prolonged survival. A class
I missed major diagnosis was that for which detection
efore death would probably not have led to a change
n management.
ESULTS
At our center 1780 adult HSCTs were performed
rom July 1986 to June 2003, of which 1268 (71%)
ere autologous and 512 (29%) were allogeneic. Of
hese patients, 122 autopsies were performed, of
hich 111 complete medical records were available
or review. Hematopoietic stem cell sources in our
tudy were 53 (48%) autologous and syngeneic, 45
41%) sibling, 11 (10%) matched unrelated donor,
nd 2 (2%) umbilical cord (Table 1). The most com-
on conditioning regimens were total body irradi-
tion-based chemotherapy protocols, most com-
only combined with cyclophosphamide with or
ithout etoposide, in 51 patients (46%). The next
ost common was the combination of busulfan and
yclophosphamide in 25 patients (23%). The re-
aining 31% of patients received a variety of che-
otherapy-based regimens. None of the patients
eviewed had received a reduced intensity or nona-
lative conditioning regimen.
Transplantation indications for the 111 patient
ecords reviewed were as follows: non-Hodgkin
ymphoma (28%), acute myelogenous leukemia
12%), acute lymphocytic leukemia (10%), chronic
yelogenous leukemia (10%), Hodgkin lymphoma
9%), ovarian cancer (8%), myelodysplastic syn-
rome (4%), breast cancer (4%), and severe aplastic
nemia (3%). There were also 2 cases (2%) of mul- diple myeloma, colon cancer, myeloﬁbrosis, and
hronic lymphocytic leukemia. There was 1 case
1%) each of renal cell carcinoma, germ cell tumor,
euroblastoma, and melanoma. Thirty-nine pa-
ients (35%) died between day 31 and day 100
fter transplantation, 30 (27%) died between day 0
o day 30, 34 (31%) from day 101 to day 365,
nd 8 (7%) died 1 year after transplantation.
Major diagnostic causes of death after allogeneic and
utologous transplantations were reviewed (Table 2). Of
he 52 patients who had received an autologous trans-
lant, the most common major diagnosis that led to
he patients’ death was nonpseudomonas bacterial
epsis or pneumonia in 9 patients (17%). Dissemi-
ated Aspergillus (n  8, 15%), progressive disease
n  7, 13%), regimen-related toxicity (n  5, 10%),
nd other fungi (n  4, 8%) made up the next 4 most
ommon causes of death. Although the principal cause
f death after allografting was disseminated Aspergillus
n 12 patients (20%), steroid-refractory graft-versus-
ost disease (n 10, 17%), progressive disease (n 6,
0%), cytomegalovirus (CMV; n 6, 10%), and fungi
ther than Aspergillus (n  4, 7%) made up the 5 most
ommon causes of death.
The premortem clinical diagnosis agreed with the
etrospective postmortem major diagnosis in 82 pa-
ients (74%; Table 3). In 29 cases (26%), postmortem
able 1. Patient Demographics (n  111)*
Characteristic n (%)
ge, median (range) 41 (16-71)
ex
Male 55 (49%)
Female 56 (51%)
iagnoses
Non-Hodgkin lymphoma 31 (28%)
Acute myelogenous leukemia 14 (12%)
Acute lymphocytic leukemia 11 (10%)
Chronic myelogenous leukemia 11 (10%)
Hodgkin lymphoma 10 (9%)
Ovarian cancer 9 (8%)
Myelodysplastic syndrome 5 (4%)
Breast cancer 5 (4%)
Severe aplastic anemia 3 (3%)
Multiple myeloma 2 (2%)
Other 10 (9%)
tem cell sources
Autologous and syngeneic 53 (48%)
Sibling 45 (41%)
Matched unrelated donor 11 (10%)
Umbilical cord 2 (2%)
Demographics of subjects that underwent an autopsy. Diagnosis is the
disease for which the transplantation was performed. Diagnoses
not listed include colon cancer (n  2), myeloﬁbrosis (n  2),
chronic lymphocytic leukemia (n  2), germ cell tumor (n  1),
renal cell carcinoma (n 1), neuroblastoma (n 1), andmelanoma
(n 1). Stem cell sources combined 52 autologous and 1 syngeneic
transplants.iagnosis was discordant with the providing team’s
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C. C. Hofmeister et al.28linical diagnosis. Of these 29 cases, 25 subjects (86%)
ere found to have overwhelming systemic infections
espite appropriate antimicrobial therapy, rapidly
rogressive disease with a poor performance status, or
regimen-related toxicity (most commonly dilated
ardiomyopathy) in a patient who was not a candidate
or aggressive treatment such as solid organ transplan-
ation. In these cases, the autopsy would not have
rovided data that would suggest an alternative
herapy that might have prevented the patient’s
eath, a class II missed diagnosis according to cri-
eria of Goldman et al [5].
Only 4 discrepancies between premortem and
ostmortem diagnoses (class I missed diagnoses) pro-
ided data that would have led to the initiation of
ew treatments (Table 4). Three cases of dissemi-
ated CMV infection were seen and 1 case demon-
trated disseminated candidiasis. In these cases, the
utopsy provided data that suggested an alternative
herapy that might have prevented the patient’s
eath. Since our hospital started using peripheral
lood to test for CMV by a hybrid capture assay in
999 [6], no further CMV discordant cases have
able 2. Causes of Death: Allogeneic versus Autologous*
Postmortem n (%)
fter allograft (n  59)
Aspergillus 12 (20%)
Refractory graft-versus-host disease 10 (17%)
Progressive disease 6 (10%)
Cytomegalovirus 6 (10%)
Other fungi (Candida, Cladosporium,
Rhizopus, Pseudoallescheria) 4 (7%)
Pseudomonas 3 (5%)
Bacteria other than Pseudomonas 3 (5%)
DAH/engraftment 3 (5%)
Bleeding diathesis, TTP 3 (5%)
Other causes 9 (15%)
fter autograft (n  52)
Bacteria other than Pseudomonas 9 (17%)
Aspergillus 8 (15%)
Progressive disease 7 (13%)
Regimen related 5 (10%)
Other fungus 4 (8%)
Pneumonia NOS 3 (6%)
PCP 3 (6%)
DAH/engraftment 3 (6%)
Other causes 10 (19%)
AH indicates diffuse alveolar hemorrhage; TTP, thrombotic
thrombocytopenic purpura; NOS, not otherwise speciﬁed; PCP,
Pneumocystis carinii pneumonia.
Other causes for allogeneic transplantation include other viruses,
PCP, veno-occlusive disease, idiopathic pneumonia syndrome,
regimen-related toxicity, diabetic ketoacidosis, and pneumonia.
Other causes for autologous transplantation include veno-occlu-
sive disease, pseudomonas, idiopathic pneumonia syndrome,
other viruses, myocardial infarction, and Swan-Ganz catheter
trauma leading to pulmonary hemorrhage.ccurred.ISCUSSION
Our study provides the largest published review to
ate of complete autopsies of subjects after HSCT.
e focused speciﬁcally on class I missed diagnoses to
ighlight the utility of the autopsy with regard to
mproving future patient care. Our ﬁndings are similar
o other reported data in that the most frequent au-
opsy discrepancies were occult infections. Infections
re widely recognized as the most common cause of
eath among peripheral blood stem cell and marrow
ransplant recipients [4,7-9]. Most of our patients died
rom disseminated fungal infections, similar to previ-
usly reported cohorts [8,10].
Only 4 (4%) autopsies reviewed in our study pro-
ided data that might have prevented a patient’s death.
ne discrepancy involved a subject with untreated
ystemic aspergillosis who was clinically diagnosed
ith pulmonary hemorrhage, other hemorrhagic
omplications and multiple system organ failure sec-
ndary to idiopathic thrombocytopenic purpura and
isseminated enterococcal infection. Another discrep-
ncy detailed an untreated coagulase-negative staphy-
ococcus catheter infection in a patient who died from
iffuse pulmonary hemorrhage secondary to throm-
ocytopenia.
able 3. Agreement between Premortem and Postmortem Causes
f Death
Postmortem Cause of Death Discordancy*
spergillus 7/20 (35%)
rogressive disease 7/13 (54%)
egimen-related toxicity 4/6 (67%)
ther bacteria 3/12 (25%)
ther fungi (Candida, Cladosporium, Rhizopus,
Pseudoallescheria) 3/8 (38%)
ytomegalovirus 3/6 (50%)
neumonia NOS 1/4 (25%)
atrogenic 1/1 (100%)
teroid-refractory graft-versus-host
disease (10) 0/41
iffuse alveolar hemorrhage/engraftment
syndrome (6)
seudomonas sepsis or pneumonia (5)
CP (5)
leeding diathesis/thrombotic
microangiopathy (4)
eno-occlusive disease (3)
diopathic pneumonia syndrome (3)
iral pneumonia or encephalitis (3)
iabetic ketoacidosis (1)
cute myocardial infarction (1)
otal 29/111 (26%)
OS indicates not otherwise speciﬁed; PCP, Pneumocystis carinii
pneumonia.
Discordancy is the number of cases in which the premortem and
postmortem causes of death did not agree from the total number
of patients with that diagnosis. The postmortem cause of death
was derived by review of the electronic and paper medical
records and autopsy report.
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Utility of Autopsy after Hematopoietic Stem Cell Transplantation 29Although infections are the most common causes
f death in autopsy studies after HSCT, newer diag-
ostic methods may decrease the risk of missed infec-
ious diagnoses. Chandrasekar et al [9] reported in
995 autopsy results of 56 subjects after HSCT and
ound that the presence of infection was not identiﬁed
r proved before death in 9 of 14 patients with CMV,
of 13 patients with yeast, and 4 of 6 patients with
spergillus. It is unclear in this trial if diagnosing these
nfections would have prevented death in those pa-
ients. However, in the past decade several newly
eveloped noninvasive tests to detect opportunistic
nfections have been routinely used such as galacto-
annan for the diagnosis of Aspergillus [11] and poly-
erase chain reaction assays to detect CMV infection
12-16]. New assays to detect disease recurrence can
ssess BCR-ABL transcripts in chronic myelogenous
eukemia [17,18] and quantitate chronic leukemia dis-
ase levels [19]. In our study, which spanned 1986 to
003, most of these noninvasive tests were not avail-
ble. Noninvasive methods to test for CMV including
eripheral blood polymerase chain reaction, antigen-
mia, and hybrid capture may have allowed earlier
ffective antiviral treatments.
There are several limitations to our retrospective
tudy. Determining the root cause of death in the
SCT population can be complex because it is often
ultifactorial and the proximate cause of death is
ften related to remote causes of death such as graft-
ersus-host disease [20]. In our study, we tried to
dentify this remote factor and use it as the cause of
eath, whereas other studies may not have used this
xact method [2,4,9]. In our study, there was subjec-
able 4. Treatable Missed Major Diagnoses*
Postmortem Cause of Death
MV A 24-y-old patient with ALL a
to be acute GVHD of the gu
cultures during the month p
had not been treated.
A 38-y-old patient with ALL a
while hospitalized for acute
respiratory failure and died.
treated.
A 26-y-old patient with Hodgk
1988 with acute left subclav
week later. Autopsy reveale
hemorrhage and had not re
isseminated candidiasis A 32-y-old patient with relaps
diathesis and increased tran
revealed systemic candidias
was thought to have died of
therapy.
MV indicates cytomegalovirus; GVHD, graft-versus-host disease;
DVT, deep venous thrombosis.
After reviewing the records of 111 subjects, there were only 4 ca
information that would have led to the initiation of new treatmivity involved in deciding whether or not a discrep- mncy was signiﬁcant to have provided data that could
ave prevented a patient’s death; we attempted to limit
his by 2-person independent chart review and discus-
ion of every case. We hypothesize that families who
onsented for autopsies were those who were most con-
erned about management or outcome, presumably be-
ause the diagnosis was felt to be in question or after a
atient’s unexpected demise. This selection biases the
tudy to show a falsely increased rate of missed diag-
oses. Selection bias must be also be acknowledged be-
ause only 111 complete patient records of 122 autopsies
erformed were available for review.
Although autopsies typically cost approximately
S $2000 per autopsy that is rarely billed to the
atient’s insurance, autopsies can have other impor-
ant roles beyond the discovery of missed diagnoses.
utopsies can play an important educational role
21,22], provide valuable tissue for research purposes
23], and supply important data for hospital microbi-
logy and epidemiology sections. Autopsies may also
rovide an emotional beneﬁt to patient’s families be-
ause it may put family members’ minds at ease in
ertain cases [24-27].
In most cases, autopsies performed after HSCT
id not provide additional information that would
ave changed management. Recently developed non-
nvasive methods for diagnosing disease and occult
nfections may further erode the role of autopsies in
iscovering missed diagnoses.
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